CER Daily Newsfeed

The Comparative Effectiveness Research Daily Newsfeed®, known for short as the CER Daily Newsfeed®, offers the latest news, research and related information on comparative effectiveness research, real-world data and evidence, value assessment and other important health care topics. 

News from Wednesday, May 28, 2025

Articles

Rescuing Value-Based Healthcare Through Better Data

(5/28, Charles Hobson, Michael Pine, Christopher Tompkins, Health Affairs Forefront) comments “...A primary challenge in finally achieving high value healthcare in the US is discovering how to harness the comprehensive and nuanced data generated in the provision of care, which is available in each patient’s EHR, to support systemic care redesign to achieve better outcomes at lower cost. Adding that key ingredient could be transformative. The system currently used to extract data from EHRs in the US, ICD-10-CM, does not adequately capture clinical detail and nuance. Gaps, limitations, and errors in describing healthcare today lead directly to our inability to accurately measure both the outcomes resulting from the care provided and the cost of that care.” Full

Trump's 340B Request Could Further Convolute Existing Program Issues

(5/27, Gabrielle Wanneh, Inside Health Policy) reports “...[Richard Frank, director of the Center on Health Policy at the Brookings Institution,] says the president’s executive order does not propose any reform that would fix the 340B program’s core issues. ‘It’s this incredibly messy, complicated program right now and if you think the problem is basically that 340B is being used to buy all sorts of drugs for circumstances where it really isn’t aimed at helping safety net organizations survive, this doesn’t do anything about that,’ Frank told IDP.” Subscription Required

Could EU Collective Procurement Counter US Most Favored Nation Policy?

(5/28, Francesca Bruce, Pink Sheet) reports “...Joint procurement, if used by member states to respond to potential pricing and access challenges caused by a US most favored nations pricing policy, would cause more uncertainty for pharmaceutical companies, warn industry representatives.” Subscription Required

Press Releases

Institute for Clinical and Economic Review Releases Draft Evidence Report on Treatments for Spinal Muscular Atrophy

(5/27, ICER Press Release) “The Institute for Clinical and Economic Review today released a Draft Evidence Report assessing the comparative clinical effectiveness and value of apitegromab (Scholar Rock Holdings), nusinersen (Spinraza®, Biogen), onasemnogene abeparvovec-xioi (Zolgensma®, Novartis), and risdiplam (Evrysdi®, Genentech) for spinal muscular atrophy (SMA).” Full

Journals

Comparative Effectiveness of Antiviral Agents and Monoclonal Antibodies for Early SARS-CoV-2 Therapy in Immunocompromised Patients: A Multicenter Retrospective Cohort Study (March 2021-March 2022)

Serena Vita, et al.

May 6, 2025, Microorganisms

PubMed

Adverse Event Costs and Cost-Effectiveness Analyses of Anticancer Drugs: A Systematic Review

Mingye Zhao, PhD; Taihang Shao, PhD; Yue Yin, PhD; et al

May 27, 2025, JAMA Network Open

JAMA Network Open

A Bayesian Approach to the Survivor Average Causal Effect in Cluster-Randomized Crossover Trials

Dane Isenberg, et al.

May 27, 2025, arXiv

arXiv

Comparative Effectiveness for Early-Stage NSCLC Without Lymph Node Involvement Based on Prospective Studies

Xue Yang, et al.

May 28, 2025, International Journal of Surgery

PubMed

Real-World Data on Trastuzumab Emtansine (TDM1) Efficacy and Safety: Results of a Single-Centre Retrospective Study of HER2-Positive Metastatic Breast Cancer Patients

Anuj Gupta, et al.

May 28, 2025, Scientific Reports

Scientific Reports

Reports

Therapiesfor Spinal Muscular Atrophy: Effectiveness and Value

May 27, 2025

ICER